首页 News 正文

On January 14th, Merck announced on January 12th local time that the US Food and Drug Administration (FDA) has approved Merck's PD-1 inhibitor Keytruda in combination with radiotherapy and chemotherapy (CRT) for the treatment of stage III-IVA cervical cancer patients as defined by the International Federation of Obstetrics and Gynecology (FIGO) 2014.
您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

胡胡胡美丽_ss 注册会员
  • 粉丝

    0

  • 关注

    0

  • 主题

    34